CD33 and acute myeloid leukemia: A target for AML immunotherapy is represented by CD33, a myeloid-specific transmembrane sialic acid-binding receptor expressed at higher levels on AML blasts and leukemic stem cells but at lower levels on normal HSCs/HPCs.